We are live on ! Find out more
KZIA

Kazia Therapeutics
KZIA

7 hedge funds and large institutions have $394K invested in Kazia Therapeutics in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $353K → $394K (+$41K)

0% more funds holding

Funds holding: 7 → 7 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$45K
2
Citadel Advisors
Citadel Advisors
Florida
+$20.2K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$7.56K
4
UBS Group
UBS Group
Switzerland
+$6.93K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$185K – – –
Morgan Stanley
2
Morgan Stanley
New York
$172K +$45K +143 +29%
Citadel Advisors
3
Citadel Advisors
Florida
$18K +$20.2K +64 New
UBS Group
4
UBS Group
Switzerland
$12K +$6.93K +22 +96%
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$7K +$7.56K +24 +2,400%

KZIA Hedge Fund Activity: Q1 2017 in Review

7 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q1 2017, worth a combined $394K — up 12% from $353K a quarter earlier.

Fund positioning in KZIA was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $45K.

  • 7 institutional investors held Kazia Therapeutics (KZIA) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $394K of Kazia Therapeutics stock for Q1 2017, up 12% quarter-over-quarter.
  • 1 fund opened new Kazia Therapeutics positions in Q1 2017 and 1 closed out, a net change of 0 holders.
  • The largest Kazia Therapeutics buyer in Q1 2017 was Morgan Stanley, an estimated $45K added.

Based on aggregated 13F filings for Q1 2017.